Page 3 - Cipla Results
Cipla Q3 profit up 7% to Rs 4 bn, India revenue swells 15% to Rs 16 bn
Revenue from North America fell 2 percent due to ongoing pricing pressures in the generics market
 "Cipla Q3 profit up 7% to Rs 4 bn, India revenue swells 15% to Rs 16 bn")
Cipla's Q4 loss narrows to Rs 62 crore, scales down biotech business
Cipla its scaling down its biotech business after a weak fourth quarter which saw Rs 61.79 crore loss. In the same quarter last fiscal the company had posted Rs 93 crore loss.While the loss declined on a year on year basis the result was way below street estimates which was anticipating Rs 200-300 crore quarterly profit. Income from operations rose 8 per cent to Rs 3582 crore largely led by growth in the US market but sales slowed down in India and other emerging markets.Impairment charge of Rs 260 crore in relation to its biotech business and litigation for certain products in the US contributed to the loss."Operationally the quarter was in line with our guidance ," Cipla's chief executive officer Umang Vohra said. He added that the reported 14 per cent Ebidta margin included the one off impact of impairment and forex loss. Vohra said the company will not manufacture biosimilars and will outsource production of or look for inlicensing opportunities. The company has also put on ...
 "Cipla's Q4 loss narrows to Rs 62 crore, scales down biotech business")
Cipla Q4 loss narrows to Rs 62 crore
Analysts on average had expected the firm would report a profit of Rs 345 crore
 "Cipla Q4 loss narrows to Rs 62 crore")
